tiprankstipranks
Trending News
More News >

Recordati Updates on Share Buyback Program Execution

Story Highlights
  • Recordati is a global pharmaceutical group offering specialty and general medicine solutions.
  • Recordati executed a share buyback, purchasing 80,423 shares to support management incentives.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Recordati Updates on Share Buyback Program Execution

Elevate Your Investing Strategy:

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an announcement.

Recordati S.p.A. announced an update on its share buyback program, which was initiated to support stock options and performance share plans for the company’s management. From June 30 to July 4, 2025, the company purchased 80,423 ordinary shares at an average price of €53.5657, increasing its total holdings to 3,623,213 shares, representing 1.733% of its share capital. This strategic move aims to strengthen the company’s market position and provide incentives for its management team.

The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, with origins in a family pharmacy in Northern Italy in the 1920s. The company provides therapeutic options in specialty and general medicine, as well as in rare diseases, and operates in about 150 countries across EMEA, Americas, and APAC regions with over 4,580 employees.

Average Trading Volume: 314,367

Technical Sentiment Signal: Strong Buy

Current Market Cap: €11.09B

Learn more about REC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1